Role of OCT1 in hepatocellular carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(9822):1245–1255. doi:10.1016/S0140-6736(11)61347-022353262
   PubMed Web of Science ®Google Scholar
• Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res. 2007;24(3):450–470. doi:10.1007/s11095-006-9181-417245646
   PubMed Web of Science ®Google Scholar
• Pelis RM, Wright SH. SLC22, SLC44, and SLC47 transporters–organic anion and cation transporters: molecular and cellular properties. Curr Top Membr. 2014;73:233–261. doi:10.1016/B978-0-12-800223-0.00006-224745985
   PubMed Web of Science ®Google Scholar
• Nigam SK. What do drug transporters really do? Nat Rev Drug Discov. 2015;14(1):29–44. doi:10.1038/nrd446125475361
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Shiew-Mei H, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215. doi:10.1038/nrd302820190787
   PubMed Web of Science ®Google Scholar
• Zhu C, Nigam KB, Date RC, et al. Evolutionary analysis and classification of OATs, OCTs, OCTNs, and other SLC22 transporters: structure-function implications and analysis of sequence motifs. PLoS One. 2015;10(11):e0140569. doi:10.1371/journal.pone.014056926536134
   PubMed Web of Science ®Google Scholar
• Koepsell H. In vivo two-photon fluorescence microscopy opens a new area for investigation of the excretion of cationic drugs in the kidney. Kidney Int. 2007;72(4):387–388. doi:10.1038/sj.ki.500223917687378
   PubMed Web of Science ®Google Scholar
• Koepsell H. Role of organic cation transporters in drug-drug interaction. Expert Opin Drug Metab Toxicol. 2015;11(10):1619–1633. doi:10.1517/17425255.2015.106927426206523
   PubMed Web of Science ®Google Scholar
• Koepsell H, Schmitt BM, Gorboulev V. Organic cation transporters. Rev Physiol Biochem Pharmacol. 2003;150:36–90.12827517
   PubMed Web of Science ®Google Scholar
• Koepsell H. Substrate recognition and translocation by polyspecific organic cation transporters. Biol Chem. 2011;392(1–2):95–101. doi:10.1515/BC.2011.00921194363
   PubMed Web of Science ®Google Scholar
• Koepsell H, Endou H. The SLC22 drug transporter family. Pflugers Arch. 2004;447(5):666–676. doi:10.1007/s00424-003-1089-912883891
   PubMed Web of Science ®Google Scholar
• Ciarimboli G. Organic cation transporters. Xenobiotica. 2008;38(7–8):936–971. doi:10.1080/0049825070188248218668435
   PubMed Web of Science ®Google Scholar
• Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet. 2005;20(6):452–477. doi:10.2133/dmpk.20.45216415531
   PubMedGoogle Scholar
• Karbach U, Kricke J, Meyer-Wentrup F, et al. Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am J Physiol Renal Physiol. 2000;279(4):F679–F687. doi:10.1152/ajprenal.2000.279.4.F67910997918
   PubMed Web of Science ®Google Scholar
• Motohashi H, Sakurai Y, Saito H, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol. 2002;13(4):866–874.11912245
   PubMed Web of Science ®Google Scholar
• Nies AT, Koepsell H, Winter S, et al. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009;50(4):1227–1240. doi:10.1002/hep.2310319591196
   PubMed Web of Science ®Google Scholar
• Grundemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H. Drug excretion mediated by a new prototype of polyspecific transporter. Nature. 1994;372(6506):549–552. doi:10.1038/372549a07990927
   PubMed Web of Science ®Google Scholar
• Gorboulev V, Ulzheimer JC, Akhoundova A, et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997;16(7):871–881. doi:10.1089/dna.1997.16.8719260930
   PubMed Web of Science ®Google Scholar
• Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S, Giacomini KM. Cloning and functional expression of a human liver organic cation transporter. Mol Pharmacol. 1997;51(6):913–921.9187257
   PubMed Web of Science ®Google Scholar
• Koehler MR, Wissinger B, Gorboulev V, Koepsell H, Schmid M. The two human organic cation transporter genes SLC22A1 and SLC22A2 are located on chromosome 6q26. Cytogenet Cell Genet. 1997;79(3–4):198–200. doi:10.1159/0001347209605850
   PubMedGoogle Scholar
• Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007;24(7):1227–1251. doi:10.1007/s11095-007-9254-z17473959
   PubMed Web of Science ®Google Scholar
• Hayer M, Bonisch H, Bruss M. Molecular cloning, functional characterization and genomic organization of four alternatively spliced isoforms of the human organic cation transporter 1 (hOCT1/SLC22A1). Ann Hum Genet. 1999;63(Pt 6):473–482. doi:10.1017/S000348009900777011388889
   PubMedGoogle Scholar
• Grundemann D, Schomig E. Gene structures of the human non-neuronal monoamine transporters EMT and OCT2. Hum Genet. 2000;106(6):627–635.10942111
   PubMed Web of Science ®Google Scholar
• Lozano E, Herraez E, Briz O, et al. Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. Biomed Res Int. 2013;2013:692071. doi:10.1155/2013/69207123984399
   PubMed Web of Science ®Google Scholar
• Wright SH. Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. Toxicol Appl Pharmacol. 2005;204(3):309–319.15845420
   PubMed Web of Science ®Google Scholar
• Burckhardt G, Wolff NA. Structure of renal organic anion and cation transporters. Am J Physiol Renal Physiol. 2000;278(6):F853–F866. doi:10.1152/ajprenal.2000.278.6.F85310836973
   PubMed Web of Science ®Google Scholar
• Hyrsova L, Smutny T, Trejtnar F, Pavek P. Expression of organic cationtransporter 1 (OCT1): unique patterns of indirect regulation by nuclear receptors and hepatospecific gene regulation. Drug Metab Rev. 2016;48(2):139–158. doi:10.1080/03602532.2016.118893627278216
   PubMed Web of Science ®Google Scholar
• Sakata T, Anzai N, Shin HJ, et al. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem Biophys Res Commun. 2004;313(3):789–793. doi:10.1016/j.bbrc.2003.11.17514697261
   PubMed Web of Science ®Google Scholar
• Marin JJ, Briz O, Monte MJ, Blazquez AG, Macias RI. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs. Curr Cancer Drug Targets. 2012;12(4):402–438.22229248
   PubMed Web of Science ®Google Scholar
• Tarasova L, Kalnina I, Geldnere K, et al. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenet Genomics. 2012;22(9):659–666. doi:10.1097/FPC.0b013e328356166622735389
   PubMed Web of Science ®Google Scholar
• Kerb R, Brinkmann U, Chatskaia N, et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics. 2002;12(8):591–595.12439218
   PubMedGoogle Scholar
• Saito S, Iida A, Sekine A, et al. Catalog of 238 variations among six human genes encoding solute carriers (hSLCs) in the Japanese population. J Hum Genet. 2002;47(11):576–584. doi:10.1007/s10038020008812436193
   PubMed Web of Science ®Google Scholar
• Itoda M, Saito Y, Maekawa K, et al. Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cationtransporter 1 (OCT1). Drug Metab Pharmacokinet. 2004;19(4):308–312. doi:10.2133/dmpk.19.30815499200
   PubMedGoogle Scholar
• Shu Y, Sheardown SA, Brown C, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest. 2007;117(5):1422–1431. doi:10.1172/JCI3055817476361
   PubMed Web of Science ®Google Scholar
• Shu Y, Leabman MK, Feng B, et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA. 2003;100(10):5902–5907. doi:10.1073/pnas.073085810012719534
   PubMed Web of Science ®Google Scholar
• Herraez E, Lozano E, Macias RI, et al. Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. Hepatology. 2013;58(3):1065–1073. doi:10.1002/hep.2642523532667
   PubMed Web of Science ®Google Scholar
• Shikata E, Yamamoto R, Takane H, et al. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J Hum Genet. 2007;52(2):117–122. doi:10.1007/s10038-006-0087-017111267
   PubMed Web of Science ®Google Scholar
• Kim DH, Sriharsha L, Xu W, et al. Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia. Clin Cancer Res. 2009;15(14):4750–4758. doi:10.1158/1078-0432.CCR-09-014519584153
   PubMed Web of Science ®Google Scholar
• Koepsell H, Gorboulev V, Arndt P. Molecular pharmacology of organic cation transporters in kidney. J Membr Biol. 1999;167(2):103–117.9916142
   PubMed Web of Science ®Google Scholar
• Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther. 2004;308(1):2–9.14576340
   PubMed Web of Science ®Google Scholar
• Ciarimboli G, Struwe K, Arndt P, et al. Regulation of the human organic cation transporter hOCT1. J Cell Physiol. 2004;201(3):420–428. doi:10.1002/jcp.2008115389554
   PubMed Web of Science ®Google Scholar
• Ingoglia F, Visigalli R, Rotoli BM, et al. Functional characterization of the organic cation transporters (OCTs) in human airway pulmonary epithelial cells. Biochim Biophys Acta. 2015;1848(7):1563–1572.25883089
   PubMed Web of Science ®Google Scholar
• Lin CJ, Tai Y, Huang MT, et al. Cellular localization of the organic cation transporters, OCT1 and OCT2, in brain microvessel endothelial cells and its implication for MPTP transport across the blood-brain barrier and MPTP-induced dopaminergic toxicity in rodents. J Neurochem. 2010;114(3):717–727. doi:10.1111/j.1471-4159.2010.06801.x20477935
   PubMed Web of Science ®Google Scholar
• Minuesa G, Purcet S, Erkizia I, et al. Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells. J Pharmacol Exp Ther. 2008;324(2):558–567.18042828
   PubMed Web of Science ®Google Scholar
• Kim MH, Shin HJ, Lim SJ, et al. Inter-individual variability in OCT1 expression and its relationship with OCT1 genotype in liver samples from a Korean population. Drug Metab Pharmacokinet. 2012;27(5):530–535. doi:10.2133/dmpk.DMPK-11-RG-10922498645
   PubMed Web of Science ®Google Scholar
• Aoki M, Terada T, Kajiwara M, et al. Kidney-specific expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation. Am J Physiol Renal Physiol. 2008;295(1):F165–F170. doi:10.1152/ajprenal.90257.200818508876
   PubMed Web of Science ®Google Scholar
• Zhang T, Xiang CD, Gale D, Carreiro S, Wu EY, Zhang EY. Drug transporter and cytochrome P450 mRNA expression in human ocular barriers: implications for ocular drug disposition. Drug Metab Dispos. 2008;36(7):1300–1307.18411399
   PubMed Web of Science ®Google Scholar
• Moreno-Navarrete JM, Ortega FJ, Rodriguez-Hermosa JI, et al. OCT1 expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes. 2011;60(1):168–176. doi:10.2337/db10-080520956498
   PubMed Web of Science ®Google Scholar
• Lee N, Hebert MF, Prasad B, et al. Effect of gestational age on mRNA and protein expression of polyspecific organic cation transporters during pregnancy. Drug Metab Dispos. 2013;41(12):2225–2232.24101703
   PubMed Web of Science ®Google Scholar
• Ito N, Ito K, Ikebuchi Y, et al. Organic cation transporter/solute carrier family 22a is involved in drug transfer into milk in mice. J Pharm Sci. 2014;103(10):3342–3348. doi:10.1002/jps.2413825175747
   PubMed Web of Science ®Google Scholar
• Gilchrist SE, Alcorn J. Lactation stage-dependent expression of transporters in rat whole mammary gland and primary mammary epithelial organoids. Fundam Clin Pharmacol. 2010;24(2):205–214.19702690
   PubMed Web of Science ®Google Scholar
• Muller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005;70(12):1851–1860.16263091
   PubMed Web of Science ®Google Scholar
• Han TK, Everett RS, Proctor WR, et al. Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes. Mol Pharmacol. 2013;84(2):182–189.23680637
   PubMed Web of Science ®Google Scholar
• Lips KS, Volk C, Schmitt BM, et al. Polyspecificcation transporters mediate luminal release of acetylcholine from bronchial epithelium. Am J Respir Cell Mol Biol. 2005;33(1):79–88. doi:10.1165/rcmb.2004-0363OC15817714
   PubMed Web of Science ®Google Scholar
• Schaeffeler E, Hellerbrand C, Nies AT, et al. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome Med. 2011;3(12):82. doi:10.1186/gm29822196450
   PubMed Web of Science ®Google Scholar
• More SS, Li S, Yee SW, et al. Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Mol Cancer Ther. 2010;9(4):1058–1069. doi:10.1158/1535-7163.MCT-09-108420371711
   PubMed Web of Science ®Google Scholar
• Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab Dispos. 2007;35(8):1333–1340.17496207
   PubMed Web of Science ®Google Scholar
• Gupta S, Wulf G, Henjakovic M, Koepsell H, Burckhardt G, Hagos Y. Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel. J Pharmacol ExpTher. 2012;341(1):16–23.
   PubMed Web of Science ®Google Scholar
• Namisaki T, Schaeffeler E, Fukui H, et al. Differential expression of drug uptake and efflux transporters in Japanese patients with hepatocellular carcinoma. Drug Metab Dispos. 2014;42(12):2033–2040.25231932
   PubMed Web of Science ®Google Scholar
• Martinez-Becerra P, Vaquero J, Romero MR, et al. No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors. Mol Pharm. 2012;9(6):1693–1704. doi:10.1021/mp300028a22524153
   PubMedGoogle Scholar
• Heise M, Lautem A, Knapstein J, et al. Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance. BMC Cancer. 2012;12:109. doi:10.1186/1471-2407-12-10922439694
   PubMed Web of Science ®Google Scholar
• Saborowski M, Kullak-Ublick GA, Eloranta JJ. The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha. J Pharmacol Exp Ther. 2006;317(2):778–785.16436500
   PubMed Web of Science ®Google Scholar
• Tirona RG, Lee W, Leake BF, et al. The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med. 2003;9(2):220–224. doi:10.1038/nm81512514743
   PubMed Web of Science ®Google Scholar
• Stoffel M, Duncan SA. The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc Natl Acad Sci USA. 1997;94(24):13209–13214. doi:10.1073/pnas.94.24.132099371825
   PubMed Web of Science ®Google Scholar
• Kamiya A, Inoue Y, Gonzalez FJ. Role of the hepatocyte nuclear factor 4alpha in control of the pregnane X receptor during fetal liver development. Hepatology. 2003;37(6):1375–1384. doi:10.1053/jhep.2003.5021212774017
   PubMed Web of Science ®Google Scholar
• Jixuan L, Gang N, Stephen AD. Mammalian hepatocyte differentiation requires the transcription factor HNF-4α. Genes Dev. 2000;14(4):464–474.10691738
   PubMed Web of Science ®Google Scholar
• Inoue Y, Hayhurst GP, Inoue J, Mori M, Gonzalez FJ. Defective ureagenesis in mice carrying a liver-specific disruption of hepatocyte nuclear factor 4alpha (HNF4alpha). HNF4alpha regulates ornithine transcarbamylase in vivo. J Biol Chem. 2002;277(28):25257–25265. doi:10.1074/jbc.M20312620011994307
   PubMed Web of Science ®Google Scholar
• Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol. 2001;21(4):1393–1403. doi:10.1128/MCB.21.4.1393-1403.200111158324
   PubMed Web of Science ®Google Scholar
• Duncan SA, Nagy A, Chan W. Murine gastrulation requires HNF-4 regulated gene expression in the visceral endoderm: tetraploid rescue of Hnf-4(-/-) embryos. Development. 1997;124(2):279–287.9053305
   PubMed Web of Science ®Google Scholar
• Watt AJ, Garrison WD, Duncan SA. HNF4: a central regulator of hepatocyte differentiation and function. Hepatology. 2003;37(6):1249–1253. doi:10.1053/jhep.2003.5027312774000
   PubMed Web of Science ®Google Scholar
• Kajiwara M, Terada T, Asaka J, et al. Regulation of basal core promoter activity of human organic cation transporter 1 (OCT1/SLC22A1). Am J Physiol Gastrointest Liver Physiol. 2008;295(6):G1211–G1216. doi:10.1152/ajpgi.90360.200818845576
   PubMed Web of Science ®Google Scholar
• Hyrsova L, Smutny T, Carazo A, et al. The pregnane X receptor down-regulates organic cation transporter 1 (SLC22A1) in human hepatocytes by competing for (“squelching”) SRC-1 coactivator. Br J Pharmacol. 2016;173(10):1703–1715. doi:10.1111/bph.1347226920453
   PubMed Web of Science ®Google Scholar
• Min G, Kim H, Bae Y, Petz L, Kemper JK. Inhibitory cross-talk between estrogen receptor (ER) and constitutively activated androstane receptor (CAR). CAR inhibits ER-mediated signaling pathway by squelching p160 coactivators. J Biol Chem. 2002;277(37):34626–34633. doi:10.1074/jbc.M20523920012114525
   PubMed Web of Science ®Google Scholar
• Cahill MA, Ernst WH, Janknecht R, Nordheim A. Regulatory squelching. FEBS Lett. 1994;344(2–3):105–108. doi:10.1016/0014-5793(94)00320-38187867
   PubMed Web of Science ®Google Scholar
• Rulcova A, Krausova L, Smutny T, et al. Glucocorticoid receptor regulates organic cation transporter 1 (OCT1, SLC22A1) expression via HNF4α upregulation in primary human hepatocytes. Pharmacol Rep. 2013;65(5):1322–1335.24399729
   PubMed Web of Science ®Google Scholar
• Kamiyama Y, Matsubara T, Yoshinari K, Nagata K, Kamimura H, Yamazoe Y. Role of human hepatocyte nuclear factor 4alpha in the expression of drug-metabolizing enzymes and transporters in human hepatocytes assessed by use of small interfering RNA. Drug Metab Pharmacokinet. 2007;22(4):287–298. doi:10.2133/dmpk.22.28717827783
   PubMed Web of Science ®Google Scholar
• Castell JV, Jover R, Martinez-Jimenez CP, Gomez-Lechon MJ. Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol. 2006;2(2):183–212. doi:10.1517/17425255.2.2.18316866607
   PubMed Web of Science ®Google Scholar
• Ciarimboli G, Koepsell H, Iordanova M, et al. Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation. J Am Soc Nephrol. 2005;16(6):1562–1570.15829703
   PubMed Web of Science ®Google Scholar
• Hui L, Zatloukal K, Scheuch H, Stepniak E, Wagner EF. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest. 2008;118(12):3943–3953. doi:10.1172/JCI3715619033664
   PubMed Web of Science ®Google Scholar
• Chang Q, Chen J, Beezhold KJ, Castranova V, Shi X, Chen F. JNK1 activation predicts the prognostic outcome of the human hepatocellular carcinoma. Mol Cancer. 2009;8:64.19686584
   PubMed Web of Science ®Google Scholar
• Lautem A, Heise M, Grasel A, et al. Downregulation of organic cation transporter 1 (SLC22A1) is associated with tumor progression and reduced patient survival in human cholangiocellular carcinoma. Int J Oncol. 2013;42(4):1297–1304. doi:10.3892/ijo.2013.184023440379
   PubMed Web of Science ®Google Scholar
• Lambert MP, Paliwal A, Vaissiere T, et al. Aberrant DNA methylation distinguishes hepatocellular carcinoma associated with HBV and HCV infection and alcohol intake. J Hepatol. 2011;54(4):705–715. doi:10.1016/j.jhep.2010.07.02721146512
   PubMed Web of Science ®Google Scholar
• Asghar U, Meyer T. Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol. 2012;56(3):686–695. doi:10.1016/j.jhep.2011.07.03121971559
   PubMed Web of Science ®Google Scholar
• Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–442. doi:10.1053/jhep.2003.5004712540794
   PubMed Web of Science ®Google Scholar
• Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer. 2010;102(1):68–72. doi:10.1038/sj.bjc.660545819935794
   PubMed Web of Science ®Google Scholar
• Geier A, Macias RI, Bettinger D, et al. The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma. Oncotarget. 2017;8(9):15846–15857. doi:10.18632/oncotarget.1502928178663
   PubMedGoogle Scholar
• Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12(4):426–437. doi:10.1634/theoncologist.12-4-42617470685
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2006;24(26):4293–4300. doi:10.1200/JCO.2005.01.344116908937
   PubMed Web of Science ®Google Scholar
• Grimm D, Lieb J, Weyer V, et al. Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment. BMC Cancer. 2016;16:94. doi:10.1186/s12885-016-2150-326872727
   PubMed Web of Science ®Google Scholar
• Zhang S, Lovejoy KS, Shima JE, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006;66(17):8847–8857. doi:10.1158/0008-5472.CAN-06-076916951202
   PubMed Web of Science ®Google Scholar
• Minematsu T, Giacomini KM. Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther. 2011;10(3):531–539. doi:10.1158/1535-7163.MCT-10-073121252289
   PubMed Web of Science ®Google Scholar
• Zach O, Krieger O, Foedermayr M, Zellhofer B, Lutz D. OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients. Leuk Lymphoma. 2008;49(11):2222–2223. doi:10.1080/1042819080232289319021069
   PubMed Web of Science ®Google Scholar
• Al-Abdulla R, Lozano E, Macias RIR, et al. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib. Br J Pharmacol. 2019;176(6):787–800. doi:10.1111/bph.1456330592786
   PubMed Web of Science ®Google Scholar
• Lozano E, Macias RIR, Monte MJ, et al. Causes of hOCT1-dependent cholangiocarcinomaresistance to sorafenib and sensitization by tumor-selective gene therapy. Hepatology. 2019 Epub ahead of print. doi:10.1002/hep.30656
   Web of Science ®Google Scholar
• Funk C. The role of hepatic transporters in drug elimination. Expert Opin Drug Metab Toxicol. 2008;4(4):363–379. doi:10.1517/17425255.4.4.36318433342
   PubMed Web of Science ®Google Scholar
• Hayer-Zillgen M, Brüss M, Bönisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002;136(6):829–836. doi:10.1038/sj.bjp.070478512110607
   PubMed Web of Science ®Google Scholar
• Gründemann D, Liebich G, Kiefer N, Köster S, Schömig E. Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999;56(1):1–10.10385678
   PubMed Web of Science ®Google Scholar
• Boxberger KH, Hagenbuch B, Lampe JN. Common drugs inhibit human organic cation transporter 1 (OCT1)-mediated neurotransmitter uptake. Drug Metab Dispos. 2014;42(6):990–995.24688079
   PubMed Web of Science ®Google Scholar
• Chen L, Shu Y, Liang X, et al. OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Nat Acad Sci USA. 2014;111(27):9983–9988. doi:10.1073/pnas.131493911124961373
   PubMed Web of Science ®Google Scholar
• Koepsell H. The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med. 2013;34(2-3):413–435. doi:10.1016/j.mam.2012.10.01023506881
   PubMed Web of Science ®Google Scholar
• Yin J, Duan H, Shirasaka Y, Prasad B, Wang J. Atenolol renal secretion is mediated by human organic cation transporter 2 and multidrug and toxin extrusion proteins. Drug Metab Dispos. 2015;43(12):1872–1881.26374172
   PubMed Web of Science ®Google Scholar
• Nies AT, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol. 2011;201:105–167.
   PubMedGoogle Scholar
• Iwai M, Minematsu T, Li Q, Iwatsubo T, Usui T. Utility of P-glycoprotein and organic cation transporter 1 double-transfected LLC-PK1 cells for studying the interaction of YM155 monobromide, novel small-molecule survivin suppressant, with P-glycoprotein. Drug Metab Dispos. 2011;39(12):2314–2320. doi:10.1124/dmd.111.04073321918035
   PubMed Web of Science ®Google Scholar
• Saadatmand AR, Tadjerpisheh S, Brockmöller J, Tzvetkov MV. The prototypic pharmacogenetic drug debrisoquine is a substrate of the genetically polymorphic organic cation transporter OCT1. Biochem Pharmacol. 2012;83(10):1427–1434.22342776
   PubMed Web of Science ®Google Scholar
• Ishiguro N, Shimizu H, Kishimoto W, Ebner T, Schaefer O. Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods. Drug Metab Dispos. 2013;41(1):149–158.23073734
   PubMed Web of Science ®Google Scholar
• Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006;319(2):879–886.16914559
   PubMed Web of Science ®Google Scholar